Executive

Mr. Hite assumed the responsibilities as CEO for both Nova Oculus Medical and Nova Oculus Canada in early 2023, has had extensive experience in life sciences, primarily pharmaceuticals and medical devices. Earlier in his career, he was recruited by the board of directors of Taiho Pharmaceutical Co., Ltd. (Japan), a member of the Otsuka Pharmaceutical Group, as CEO to startup Taiho’s first offshore subsidiary, its global clinical trials and business development unit in Princeton, New Jersey, responsible for clinical trial management and business development across three continents.  He led the out-license of Taiho’s primary drug to Sanofi-Aventis (France), which was valued at $1.7B

Mr. Hite has also started three additional companies in Japan, Cambridge, MA and the Research Triangle Park in North Carolina in pharmaceuticals and medical devices. In these roles he was responsible for all fundraising, corporate management and product commercialization, including out-licensing.  In all Mr. Hite has booked over $13B in business deals over the course of his career.  He is confident that his work at Nova Oculus will be his biggest achievement yet.

Ms. Hernandez has been the lifeblood of Nova Oculus since its beginnings a decade ago. She manages our high-level investor relations, oversees a host of databases, and nurtures our critical relationships with clients and vendors by aligning her day-to-day work with her values of reliability and integrity.

Ms. Hernandez is a native of the San Francisco Bay area, where for 14 years, she held multiple senior management positions with legal firms in Santa Clara, including the Chugh Firm, Fragomen, Del Rey, Bernsen & Loewy and the Pearl Law Group.

From the outset Ms. Hernandez understood the critical importance of the Nova Oculus therapeutic as the only known effective medical treatment for Age-Related Macular Degeneration and has dedicated herself to brining our therapeutic device, the Nova Oculus III, to the world markets.